AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Roche logo

Roche

Status

Completed

Conditions

Breast Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01777932
ML21647

Details and patient eligibility

About

This multicenter, single-arm observational study will evaluate the clinical benefits of Avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with metastatic breast cancer. Patients with metastatic breast cancer who have started Avastin treatment within 6 months prior to study start will also be eligible. Data will be collected from patients for up to 5 years.

Enrollment

220 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with metastatic breast cancer initiated on first-line treatment with Avastin in combination with paclitaxel according to the current Hungarian summary of Product Characteristics
  • Patients with metastatic breast cancer initiated within 6 months before the start of the study on treatment with Avastin according to the current Hungarian Summary of Product Characteristics

Exclusion criteria

Contraindications for Avastin according to the current Hungarian Summary of Product Characteristics:

  • Hypersensitivity to active ingredient of Avastin or to any excipients
  • Hypersensitivity to products produced in Chinese hamster cells or to other recombinant or humanized antibodies
  • Pregnancy
  • Untreated central nervous system metastases

Trial design

220 participants in 1 patient group

Cohort

Trial contacts and locations

32

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems